1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,442 | 0,455 | 30.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.07. | Oncodesign Precision Medicine - Precision therapies for resistant diseases | 278 | Edison Investment Research | Oncodesign Precision Medicine (OPM) is a clinical-stage biopharmaceutical company listed on Euronext Growth Paris. OPM is developing precision medicine therapies targeting treatment-resistant and metastatic... ► Artikel lesen | |
| 17.04. | Oncodesign Precision Medicine Announces Equity Financing of up to 5 Million Euros | 290 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 03.04. | Oncodesign Precision Medicine: OPM Announces Its 2024 Annual Results and Clinical Developments | 300 | Business Wire | OPM-101: preclinical work establishing POC in immuno-oncology, end of phase 1 healthy volunteers and preparation for phase 1b/2a Reintegration of OPM-201 into OPM's portfolio of proprietary... ► Artikel lesen | |
| 24.03. | Oncodesign Precision Medicine (OPM) Announces Protocol Submission for its Phase 1b/2a Study, REVERT for OPM-101 in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant to Anti-PD1 | 394 | Business Wire | OPM-101 will be evaluated in a Phase 1b/2a clinical trial, in combination with pembrolizumab, a monoclonal antibody directed against the PD-1 protein, in patients with advanced melanoma resistant... ► Artikel lesen | |
| 04.03. | Oncodesign Precision Medicine: Nomination of Christophe Thurieau as an Independent Member of OPM Board of Directors | 348 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 20.12.24 | Oncodesign Precision Medicine Reacquires Rights to Its OPM-201 Program From Servier After a Positive Phase I Trial in Healthy Volunteers | 399 | Business Wire | Retrieval by OPM of all rights to the OPM-201 program and associated patent portfolio Confirmation of the molecule's safety in healthy volunteers
Regulatory News:
Oncodesign Precision... ► Artikel lesen | |
| 22.10.24 | Oncodesign Precision Medicine: OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a | 390 | Business Wire | Finalization of the study report on the double-blind, placebo-controlled Phase 1 trial of OPM-101 in 104 healthy volunteers (HV) who received OPM-101 24-hour ECG analysis reveals no toxic... ► Artikel lesen | |
| ONCODESIGN PRECISION MEDICINE Aktie jetzt für 0€ handeln | |||||
| 15.10.24 | Oncodesign Precision Medicine: OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference | 334 | Business Wire | Presentation by Professor Laurent Peyrin-Biroulet (M.D., PhD Professor of Gastroenterology at CHRU of Nancy) and Bruno Robin (PharmD, Head of OPM Clinical Development) of safety, pharmacokinetic... ► Artikel lesen | |
| 25.09.24 | Oncodesign Precision Medicine: OPM Announces Its First-half 2024 Results and Provides an Update on Its Clinical Developments, and Its Financial Situation | 419 | Business Wire | OPM-101 successfully completed its Phase 1 trial with healthy volunteers, enabling the company to anticipate the start of a Phase 1b/2a clinical trial in 2024/early 2025. OPM-201, licensed... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,180 | -0,24 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| EVOTEC | 7,378 | -0,30 % | Fast 200 % Kurspotenzial! Evotec, Plug Power, Empire Brand Building Aktie | Erstmals haben Analysten den Newcomer Empire Brand Building unter die Lupe genommen. Sie sehen bei dem Schweizer Betreiber von Social Media- und E-Commerce-Plattformen für Familien fast 200 % Kurspotenzial.... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 30,060 | -1,12 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 36,880 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
| BIONTECH | 96,50 | 0,00 % | BioNTech Aktie: In welche Richtung wird es gehen? | © Foto: fn SymbolbildDas deutsche Biotech-Unternehmen BioNTech steht vor einer großen Veränderung. Die erfolgreiche Zeit mit Corona-Impfstoffen geht stetig weiter zu Ende. Jetzt arbeitet das Mainzer... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,805 | 0,00 % | Recursion Pharmaceuticals: Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th | ||
| IMMUNOME | 10,750 | +1,18 % | Immunome Inc. - 8-K, Current Report | ||
| REPLIMUNE | 6,600 | +102,45 % | Pre-market Movers: Replimune, Tigo Energy, Safe and Green Development, Fundamental Global, LendingClub Corporation | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Replimune Group, Inc. (REPL) is up over 68% at... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,140 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,590 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 50,56 | 0,00 % | ROUNDUP/Aktien New York Schluss: Gewinne - Arbeitsmarktdaten stützen | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben am Dienstag nach einem verhaltenen Start ihre Kursgewinne ausgebaut. Marktbeobachter verwiesen darauf, dass die jüngsten Daten vom US-Arbeitsmarkt trotz... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 6,900 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 | - Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 56,61 | +1,16 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies | The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,815 | +8,10 % | Sarepta-Aktie: Spekulative Chancen | Manche Aktien wirken wie toxisches Terrain - und gerade dann könnten sie besonders spannend sein. Sarepta Therapeutics ist tief gefallen und Analysten sehen sogar den möglichen Totalverlust. Aber wer... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,660 | 0,00 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald |
ONCODESIGN PRECISION MEDICINE SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -9,13 % bei einem Aktienkurs von 0,428 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCODESIGN PRECISION MEDICINE SA finden Sie auf Wallstreet Online.